1955-P: Interleukin-1ß Orchestrates Non–Glucose Dependent Cephalic Phase Insulin Release in Health and Obesity
| Autor: | Kelly Trimigliozzi, Marianne Boeni-Schnetzler, Daniel T. Meier, Erez Dror, Sophia J. Wiedemann, Theresa V. Rohm, Friederike Schulze, Jose Alberto Molina-Tijeras, Hélène Méreau, Marc Y. Donath, Leila Rachid, Christophe Magnan, Stéphanie P. Häuselmann |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Interleukin Cephalic phase Carbohydrate metabolism medicine.disease Obesity Blockade Endocrinology Postprandial Diabetes mellitus Internal medicine Internal Medicine medicine business |
| Zdroj: | Diabetes. 69 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | The non-glucose dependent spike in insulin levels immediately following the beginning of a meal is called the cephalic or pre-absorptive phase of insulin secretion. Even though this early insulin response is of marked consequence for overall postprandial insulin release, its basic mechanisms remain largely unexplored. Here, we show that both genetic and pharmacologic blockade of interleukin-1β (IL-1β) leads to a pronounced reduction in cephalic phase insulin secretion (-0.65 [95%CI= -1.137 to -0.172]). Assessing mice fed a high-fat diet, we found that the cephalic phase insulin response was abolished in obesity. In a systematic review and meta-analysis of trials studying cephalic phase insulin release in healthy human volunteers, we found that this was equally the case in humans. In contrast, high-fat diet-fed mice pre-treated with a specific anti-IL-1β antibody once a week developed no such impairment. We therefore conclude, that dysregulation of physiologic IL-1β signaling, specifically during cephalic phase, may contribute to the overall pathology of metabolic disease. Thus, we identify cephalic phase inflammatory signaling as a novel and potentially modifiable target in the regulation of glucose metabolism. Disclosure S.J. Wiedemann: None. E. Dror: None. D.T. Meier: None. K. Trimigliozzi: None. J. Molina-Tijeras: None. F. Schulze: None. L. Rachid: None. S.P. Häuselmann: None. T.V. Rohm: None. H. Mereau: None. C. Magnan: None. M. Boeni-Schnetzler: None. M.Y. Donath: Advisory Panel; Self; AstraZeneca, Bayer Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk Inc., Roche Pharma, Sanofi-Aventis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|